603896 Zhejiang Shouxiangu Pharmaceutical
- 22.22
- +0.56+2.59%
Zhejiang Shouxiangu Pharmaceutical News
Shou Xian Valley (603896): 2024H1 revenue declined slightly, and market channels expanded steadily
Shouxianggu (603896): Performance is under phased pressure to look forward to the results of the reform
Shou Xian Valley (603896): The whole industry chain+technological innovation builds the company's core advantages
Shou Xian Valley (603896): Making up for shortcomings in marketing, stronger scientific research, and looking forward to continued restoration of demand
Shouxiangoku (603896): Short-term performance is pressured and the share of online sales continues to rise
Shouxianggu (603896): Business picked up in the first quarter, sales and R&D progressed steadily
Shouxianggu (603896): 2023 results are under pressure, and the 2024Q1 business recovery is worth looking forward to throughout the year
Shouxianggu (6038969) 2023 Report and 2024Q1 Quarterly Report Review Report: 2024Q1 results ushered in the recovery and long-term development of the company
Shusengoku (603896): Performance is in line with expectations, profit levels have improved
Shouxianggu (603896): Short-term performance is under pressure, business picks up in 2024Q1
Shou Xian Valley (603896): Quarterly Report Growth Gradually Resumes Diversified Marketing Continues to Expand Channel Growth Space
China Post Securities released a research report on April 28 stating that it gave Shouxiangoku (603896.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance is under pressure, and the growth in the first quarterly report
Shouxiangu (603896) Company Information Update Report: Revenue and Profit Are Slightly Pressured, Marketing Reform Empowers Brand Development
Shou Xian Valley (603896): Weak demand in 23 years, performance under pressure, focus on the core strategy of “marketing and enterprise development”
Shusengoku (603896): Expecting improvements after 24 years of low operating conditions
Shouxianggu (603896) In-depth Report: Excellent Ganoderma lucidum spore powder products and stable channels to help growth
Shouxiangu (603896): 100 years of Ganoderma lucidum brand channel expansion and capacity growth
Shouxiangu (603896): Short-term revenue pressure continues to push forward expansion outside the province
Review of the Three Quarterly Report of Shouxiangu (603896): Performance under pressure after the pandemic
Shouxiangu (603896): Q3 revenue continues to be steady, profit is under slight pressure
Analysis
Price Target
No Data
No Data